Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00876187 · ClinicalTrials.gov registry record · Phase 2
A Study of Tanezumab in Adults With Chronic Low Back Pain
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,359
- Enrollment target
NCT00876187 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 1,359 participants.
The verdict
NCT00876187, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,359 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of multiple doses of tanezumab administered every 8 weeks in treating chronic low back pain. Tanezumab is a monoclonal antibody directed against human nerve growth factor.
Interventions
- BIOLOGICAL Tanezumab 20 mg IV
- DRUG Placebo for naproxen
- BIOLOGICAL Tanezumab 10 mg IV
- BIOLOGICAL Tanezumab 5 mg IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,359 participants |
| Start Date | 2009-06-15 |
| Est. Completion | 2011-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00876187
The ClinicalTrials.gov registry entry for NCT00876187 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,359 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Tanezumab 20 mg IV is the first listed.
NCT00876187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00876187 about?
NCT00876187 is a clinical study titled "A Study of Tanezumab in Adults With Chronic Low Back Pain". The purpose of this study is to evaluate the efficacy and safety of multiple doses of tanezumab administered every 8 weeks in treating chronic low back pain. Tanezumab is a monoclonal antibody directed against human nerve growth factor.
What is the current status of trial NCT00876187?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,359 participants. The study started on 2009-06-15. Estimated completion is 2011-02-01.
What interventions are being tested in trial NCT00876187?
The interventions under investigation include: Tanezumab 20 mg IV (BIOLOGICAL), Placebo for naproxen (DRUG), Tanezumab 10 mg IV (BIOLOGICAL), Tanezumab 5 mg IV (BIOLOGICAL).
Who is sponsoring clinical trial NCT00876187?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.